CN102481253B - 包含羟基氯喹的用于抗癌治疗的局部投药用注射剂组合物 - Google Patents

包含羟基氯喹的用于抗癌治疗的局部投药用注射剂组合物 Download PDF

Info

Publication number
CN102481253B
CN102481253B CN201080028073.1A CN201080028073A CN102481253B CN 102481253 B CN102481253 B CN 102481253B CN 201080028073 A CN201080028073 A CN 201080028073A CN 102481253 B CN102481253 B CN 102481253B
Authority
CN
China
Prior art keywords
sarcoma
present
cell
hydroxychloroquine
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080028073.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102481253A (zh
Inventor
吕旿荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102481253A publication Critical patent/CN102481253A/zh
Application granted granted Critical
Publication of CN102481253B publication Critical patent/CN102481253B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201080028073.1A 2009-06-24 2010-06-18 包含羟基氯喹的用于抗癌治疗的局部投药用注射剂组合物 Expired - Fee Related CN102481253B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0056251 2009-06-24
KR1020090056251A KR101208587B1 (ko) 2009-06-24 2009-06-24 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
PCT/KR2010/003938 WO2010151005A2 (ko) 2009-06-24 2010-06-18 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물

Publications (2)

Publication Number Publication Date
CN102481253A CN102481253A (zh) 2012-05-30
CN102481253B true CN102481253B (zh) 2014-06-25

Family

ID=43387011

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080028073.1A Expired - Fee Related CN102481253B (zh) 2009-06-24 2010-06-18 包含羟基氯喹的用于抗癌治疗的局部投药用注射剂组合物

Country Status (9)

Country Link
US (1) US8506973B2 (ja)
EP (1) EP2465494A4 (ja)
JP (1) JP5580409B2 (ja)
KR (1) KR101208587B1 (ja)
CN (1) CN102481253B (ja)
AU (1) AU2010263479B2 (ja)
BR (1) BRPI1010073A2 (ja)
RU (1) RU2554497C2 (ja)
WO (1) WO2010151005A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2681703T3 (es) * 2011-03-21 2018-09-14 Vivolux Ab Tratamiento de tumores sólidos
CN102731393B (zh) * 2012-06-27 2013-11-13 武汉武药科技有限公司 羟基氯喹衍生物及其合成方法
ES2734479T3 (es) 2012-09-21 2019-12-10 Vivolux Ab Medios y métodos para tratar tumores sólidos
RU2668560C2 (ru) 2013-03-29 2018-10-02 Сумитомо Дайниппон Фарма Ко., Лтд. Конъюгированная вакцина на основе пептида антигена wt1
CN105982896A (zh) * 2015-02-15 2016-10-05 广州中医药大学科技产业园有限公司 羟基氯喹在治疗或预防肿瘤中的用途
US20180140691A1 (en) * 2015-05-20 2018-05-24 Sumitomo Dainippon Pharma Co., Ltd. Combination use of wt1 antigen peptide and immunomodulator
KR101698003B1 (ko) 2016-06-20 2017-01-19 여오영 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
EP3498717B1 (en) * 2016-08-12 2022-05-04 The Catholic University of Korea Industry-Academic Cooperation Foundation Composition for hardening soft tissue
CN115317482A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 氯喹及其衍生物在制备改善鼻咽癌预后药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013826A1 (en) * 2000-08-02 2002-02-21 Keum Ki Chang Anti-cancer composition composed of anti-cancer and anti-malarial drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314894A (en) * 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
AU777620B2 (en) * 1999-04-09 2004-10-21 Jessie L.S. Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
CA2595156A1 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
US20080279851A1 (en) * 2007-05-07 2008-11-13 Medlmmune, Llc Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013826A1 (en) * 2000-08-02 2002-02-21 Keum Ki Chang Anti-cancer composition composed of anti-cancer and anti-malarial drugs

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Anna R. Martirosyan et al.Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model.《Biochemical Pharmacology》.2004,第68卷(第9期),第1729-1738页.
Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model;Anna R. Martirosyan et al;《Biochemical Pharmacology》;20041101;第68卷(第9期);第1729-1738页，尤其1729页摘要第1-5行，第1734-1735页第2.4 节，图4A *
Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors;L. LAGNEAUX et al;《British Journal of Haematology》;20011231;第112卷;第344-352页 *
Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio;LAURENCE LAGNEAUX et al;《Leukemia and Lymphoma》;20021231;第43卷(第5期);第1087-1095页 *
L. LAGNEAUX et al.Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors.《British Journal of Haematology》.2001,第112卷第344-352页.
LAURENCE LAGNEAUX et al.Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio.《Leukemia and Lymphoma》.2002,第43卷(第5期),第1087-1095页.
Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine;Patricia Boya et al;《Oncogene》;20031231;第22卷;第3927–3936页 *
Patricia Boya et al.Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine.《Oncogene》.2003,第22卷第3927–3936页.
周建平.第一篇 药剂学基础知识.《药剂学》.东南大学出版社,2007,(第1版),第119页. *

Also Published As

Publication number Publication date
AU2010263479A1 (en) 2012-02-09
KR20100137962A (ko) 2010-12-31
US20120095045A1 (en) 2012-04-19
JP5580409B2 (ja) 2014-08-27
WO2010151005A3 (ko) 2011-05-19
US8506973B2 (en) 2013-08-13
EP2465494A2 (en) 2012-06-20
EP2465494A4 (en) 2013-02-27
WO2010151005A2 (ko) 2010-12-29
CN102481253A (zh) 2012-05-30
RU2012100622A (ru) 2013-07-27
KR101208587B1 (ko) 2012-12-06
RU2554497C2 (ru) 2015-06-27
AU2010263479B2 (en) 2014-05-01
JP2012530697A (ja) 2012-12-06
BRPI1010073A2 (pt) 2016-03-15

Similar Documents

Publication Publication Date Title
CN102481253B (zh) 包含羟基氯喹的用于抗癌治疗的局部投药用注射剂组合物
Cheng et al. Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway
CN106177187B (zh) 具有增效减毒抗肝癌作用的茶多酚茶多糖组合物
Jin et al. Combination therapy with metformin and IL-12 to inhibit the growth of hepatic carcinoma by promoting apoptosis and autophagy in HepG2-bearing mice.
CN105963699B (zh) Fats作为黑色素瘤免疫治疗的靶点及应用
CN114344295B (zh) 抑制剂brd4770在制备预防和治疗主动脉夹层的药物中的应用和其药物组合物
CN110075269A (zh) Murabutide在制备电离辐射致骨髓、小肠和脾脏损伤防治药物中应用
KR102316961B1 (ko) 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물
Koike et al. Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect
CN111000851B (zh) 丹参酮i在制备肿瘤细胞自噬诱导剂药物中的应用
Mady Antitumor and biochemical effects of Echis coloratus crude venom on Ehrlich ascites carcinoma cells in vivo
CN114599379A (zh) 一种用于预防或治疗脓毒症的药物组合物、试剂盒及其应用和治疗方法
Luo et al. Low-intensity pulsed ultrasound alleviating myelosuppression of Sprague-Dawley rats after combined treating by paclitaxel and carboplatin
Niu et al. The in vivo roles of galectin-2 from Nile tilapia (Oreochromis niloticus) in immune response against bacterial infection
Maráz et al. Intrinsic alteration of lymphocyte reactivity in women with normal pregnancy or tumor of placental origin
CN104997775B (zh) 长春西汀在制备抗肺纤维化药物中的应用
CN114028407B (zh) 一种醉茄素a在制备抗肿瘤药物中的应用
CN114948941B (zh) 青蒿素的新应用以及药物组合物
CN116549468A (zh) 用于治疗肿瘤的联合药物
Tripathi et al. 192: Effect of green tea extract on cardiac transplantation
CN102949399B (zh) 丹参酮iia在制备抑制角质形成细胞增殖疾病药中的应用
CN106166296A (zh) 一种辅助雷帕霉素治疗多种肿瘤的药物组合物
CN109913413B (zh) 一种加载pd-1抗体的t细胞体外培养方法、其细胞制剂及其应用
Sacks Chang et al.
CN117531018A (zh) 一种用于治疗胶质母细胞瘤的药物组合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140625

Termination date: 20150618

EXPY Termination of patent right or utility model